Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics FGFR3 Mutation Assays

Rosetta Genomics said today that it will commercially launch two FGFR3 gene mutation assays next week at the American Urological Association annual meeting.

One assay is intended for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive low-grade bladder cancers, while the other is intended to be used in conjunction with Ki67 expression to tissue-based prognostication at the initial diagnosis of bladder cancer. The microRNA tests are designed to be used in conjunction the company's FISH technology to help urologists better manage patients through improved prognostication and non-invasive recurrence monitoring, Rosetta said.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more